Research programme: Huntington's disease therapeutics - AMRI/CHDI
Latest Information Update: 16 Jul 2016
At a glance
- Originator AMRI; CHDI
- Mechanism of Action Mitogen-activated protein kinase 10 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Huntington's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Huntington's-disease in USA
- 30 Apr 2009 Early research in Huntington's disease in USA (unspecified route)